This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Single-dose RepliVax vaccine to prevent tick-borne encephalitis (TBE)	<p>A single-cycle virus vaccine platform, RepliVax, could help generate vaccines to protect against TBE. The single-cycle virus vaccine (RepliVax-TBE) was constructed using a West Nile virus backbone with deletion of the capsid gene and insertion of TBE virus envelope genes. In outbred mice, intraperitoneal immunization with RepliVax-TBE induced a protective immune response and increased survival against a lethal challenge with a TBE-related virus compared with mock immunization. In nonhuman primates, a single dose of RepliVax-TBE protected from challenge with a TBE-related virus and induced more durable immune responses compared with an inactivated human TBE virus vaccine. Next steps include evaluating the breadth of protection conferred by RepliVax-TBE against circulating wild-type TBE strains representing three major genotypes.</p> <p>SciBX 6(31); doi:10.1038/scibx.2013.844 Published online Aug. 15, 2013</p>	Patented by Sanofi Pasteur; licensing status undisclosed	<p>Rumyantsev, A.A. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online July 15, 2013; doi:10.1073/pnas.1306245110</p> <p>Contact: Konstantin V. Pugachev, Sanofi Pasteur, Discovery US, Cambridge, Mass. e-mail: konstantin.pugachev@sanofipasteur.com</p>